Besides, TWEAK- or Fn14-targeted agents, including monoclonal antibodies (BIIB-023), fusion proteins, and immunotoxins, were developed for the therapy of RA and lupus nephritis (NCT00771329, NCT01499355, NCT01930890). This evidence concerns the gene TNFRSF12A and lupus nephritis.